Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML

Background Acute myeloid leukemia (AML) stem cells (LSCs) are capable of surviving current standard chemotherapy and are the likely source of deadly, relapsed disease. While stem cell transplant serves as proof-of-principle that AML LSCs can be eliminated by the immune system, the translation of exi...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	R Eric Davis, Marina Konopleva, Natalia Baran, Gheath Al-Atrash, Naval Daver, Shelley Herbrich, Tianyu Cai, Connie Weng, Marisa J L Aitken, Sean M Post, Jared Henderson, Chunhua Shi, Guillame Richard-Carpentier, Guy Sauvageau, Keith Baggerly, Dongxing Zha, Ondrej Havranek
Format:	article
Langue:	EN
Publié:	BMJ Publishing Group 2021
Sujets:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/ec9bd9e5fbea4ec3b2a31d083604c1bd
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML

Documents similaires